Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 8, 2016, Pages 4590-4599

  Almeida, Deepak ^a   Ioerger, Thomas ^b   Tyagi, Sandeep ^a   Li, Si Yang ^a   Mdluli, Khisimuzi ^c   Andries, Koen ^d   Grosset, Jacques ^a   Sacchettini, Jim ^b   Nuermberger, Eric ^a,e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPEPTIDASE; BEDAQUILINE; CLOFAZIMINE; ETHAMBUTOL; ISONIAZID; LINEZOLID; MOXIFLOXACIN; PRETOMANID; PYRAZINAMIDE; RESERPINE; RIFAMPICIN; VERAPAMIL; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; FEMALE; GENE MUTATION; GENETIC COMPLEMENTATION; LOSS OF FUNCTION MUTATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUBERCULOSIS; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MUTATION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANIMALS; ANTITUBERCULAR AGENTS; CLOFAZIMINE; DIARYLQUINOLINES; FEMALE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84979523473     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00753-16     Document Type: Article

References (47)

1. Matteelli A, Migliori GB, Cirillo D, Centis R, Girard E, Raviglione M. 2007. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev Anti Infect Ther 5:857-871. http://dx.doi.org/10.1586/14787210.5.5.857.
2. Cohen J. 2013. Infectious disease. Approval of novel TB drug celebrated - with restraint. Science 339:130. http://dx.doi.org/10.1126/science.339.6116.130.
3. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227. http://dx.doi.org/10.1126/science.1106753.
4. Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, Ristic Z, Lill H, Dorange I, Guillemont J, Bald D, Andries K. 2007. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 3:323-324. http://dx.doi.org/10.1038/nchembio884.
5. Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S, Andersson DI. 2010. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 54:1022-1028. http://dx.doi.org/10.1128/AAC.01611-09.
6. Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, de Jong BC, Koul A. 2014. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 9:e102135. http://dx.doi.org/10.1371/journal.pone.0102135.
7. Hartkoorn RC, Upekar S, Cole ST. 3 March 2014. Cross-resistance between clofazimine and bedaquiline through up-regulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother http://dx.doi.org/10.1128/AAC.00037-14.
8. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. 2010. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182:684-692. http://dx.doi.org/10.1164/rccm.201001-0077OC.
9. Piubello A, Harouna SH, Souleymane MB, Boukary I, Morou S, Daouda M, Hanki Y, Van Deun A. 2014. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 18:1188-1194. http://dx.doi.org/10.5588/ijtld.13.0075.
10. Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, Rieder HL. 2014. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 18:1180-1187. http://dx.doi.org/10.5588/ijtld.14.0100.
11. Tasneen R, Li SY, Peloquin CA, Taylor D, Williams KN, Andries K, Mdluli KE, Nuermberger EL. 2011. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 55:5485-5492. http://dx.doi.org/10.1128/AAC.05293-11.
12. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH. 2004. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 169:421-426. http://dx.doi.org/10.1164/rccm.200310-1380OC.
13. Larsen MH, Biermann K, Tandberg S, Hsu T, Jacobs WR, Jr. 2007. Genetic manipulation of Mycobacterium tuberculosis. Curr Protoc Microbiol Chapter 10:Unit 10A.2. http://dx.doi.org/10.1002/9780471729259.mc10a02s6.
14. Ioerger TR, Feng Y, Ganesula K, Chen X, Dobos KM, Fortune S, Jacobs WR, Jr, Mizrahi V, Parish T, Rubin E, Sassetti C, Sacchettini JC. 2010. Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories. J Bacteriol 192:3645-3653. http://dx.doi.org/10.1128/JB.00166-10.
15. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408. http://dx.doi.org/10.1006/meth.2001.1262.
16. Ibrahim M, Andries K, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V, Veziris N. 2007. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 51:1011-1015. http://dx.doi.org/10.1128/AAC.00898-06.
17. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE, III, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544. http://dx.doi.org/10.1038/31159.
18. Sassetti CM, Boyd DH, Rubin EJ. 2003. Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48:77-84. http://dx.doi.org/10.1046/j.1365-2958.2003.03425.x.
19. Lu Y, Zheng M, Wang B, Fu L, Zhao W, Li P, Xu J, Zhu H, Jin H, Yin D, Huang H, Upton AM, Ma Z. 2011. Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation. Antimicrob Agents Chemother 55:5185-5193. http://dx.doi.org/10.1128/AAC.00699-11.
20. Lowther WT, McMillen DA, Orville AM, Matthews BW. 1998. The anti-angiogenic agent fumagillin covalently modifies a conserved activesite histidine in the Escherichia coli methionine aminopeptidase. Proc Natl Acad Sci U S A 95:12153-12157. http://dx.doi.org/10.1073/pnas.95.21.12153.
21. Zheng Y, Roberts RJ, Kasif S, Guan C. 2005. Characterization of two new aminopeptidases in Escherichia coli. J Bacteriol 187:3671-3677. http://dx.doi.org/10.1128/JB.187.11.3671-3677.2005.
22. Coll M, Knof SH, Ohga Y, Messerschmidt A, Huber R, Moellering H, Russmann L, Schumacher G. 1990. Enzymatic mechanism of creatine amidinohydrolase as deduced from crystal structures. J Mol Biol 214:597-610. http://dx.doi.org/10.1016/0022-2836(90)90201-V.
23. Bazan JF, Weaver LH, Roderick SL, Huber R, Matthews BW. 1994. Sequence and structure comparison suggest that methionine aminopeptidase, prolidase, aminopeptidase P, and creatinase share a common fold. Proc Natl Acad Sci U S A 91:2473-2477. http://dx.doi.org/10.1073/pnas.91.7.2473.
24. Kelley LA, Sternberg MJ. 2009. Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc 4:363-371. http://dx.doi.org/10.1038/nprot.2009.2.
25. Weaver J, Watts T, Li P, Rye HS. 2014. Structural basis of substrate selectivity of E. coli prolidase. PLoS One 9:e111531. http://dx.doi.org/10.1371/journal.pone.0111531.
26. Wilce MC, Bond CS, Dixon NE, Freeman HC, Guss JM, Lilley PE, Wilce JA. 1998. Structure and mechanism of a proline-specific aminopeptidase from Escherichia coli. Proc Natl Acad Sci U S A 95:3472-3477. http://dx.doi.org/10.1073/pnas.95.7.3472.
27. Coeck N, Villelas C, Meehan CJ, Lounis N, Niemann S, Rigouts L, de Jong B, Andries K. 2015. Unexpected high frequency of Rv0678 mutations in MDR-TB patients without documented prior use of clofazimine or bedaquiline. Int J Tuberc Lung Dis 19:S45.
28. Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, Van Baelen B, van Heeswijk RP, Dannemann B, TMC207-C209 Study Group. 2016. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 47:564-574. http://dx.doi.org/10.1183/13993003.00724-2015.
29. Zhang S, Chen J, Cui P, Shi W, Zhang W, Zhang Y. 2015. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 70:2507-2510. http://dx.doi.org/10.1093/jac/dkv150.
30. Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, Wallis RS, Mdluli KE, Nuermberger EL. 2012. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 56:3114-3120. http://dx.doi.org/10.1128/AAC.00384-12.
31. Rouan MC, Lounis N, Gevers T, Dillen L, Gilissen R, Raoof A, Andries K. 2012. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis. Antimicrob Agents Chemother 56:1444-1451. http://dx.doi.org/10.1128/AAC.00720-11.
32. European Committee on Antimicrobial Susceptibility Testing. 2014. Workshop on recommendations for pharmaceutical companies regarding data required for new antituberculous drugs, 11-12 November 2014, Basel, Switzerland. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Mycobacteria/Mycobacterial-workshop-Basel-11-12Nov2014.pdf.
33. Ioerger TR, Feng Y, Chen X, Dobos KM, Victor TC, Streicher EM, Warren RM, Gey van Pittius NC, Van Helden PD, Sacchettini JC. 2010. The non-clonality of drug resistance in Beijing-genotype isolates of Mycobacterium tuberculosis from the Western Cape of South Africa. BMC Genomics 11:670. http://dx.doi.org/10.1186/1471-2164-11-670.
34. Matos J, Nardi M, Kumura H, Monnet V. 1998. Genetic characterization of pepP, which encodes an aminopeptidase P whose deficiency does not affect Lactococcus lactis growth in milk, unlike deficiency of the X-prolyl dipeptidyl aminopeptidase. Appl Environ Microbiol 64:4591-4595.
35. Ribeiro-Guimaraes ML, Pessolani MC. 2007. Comparative genomics of mycobacterial proteases. Microb Pathog 43:173-178. http://dx.doi.org/10.1016/j.micpath.2007.05.010.
36. Harris JK, Kelley ST, Spiegelman GB, Pace NR. 2003. The genetic core of the universal ancestor. Genome Res 13:407-412. http://dx.doi.org/10.1101/gr.652803.
37. Ben-Bassat A, Bauer K, Chang SY, Myambo K, Boosman A, Chang S. 1987. Processing of the initiation methionine from proteins: properties of the Escherichia coli methionine aminopeptidase and its gene structure. J Bacteriol 169:751-757.
38. Hirel PH, Schmitter MJ, Dessen P, Fayat G, Blanquet S. 1989. Extent of N-terminal methionine excision from Escherichia coli proteins is governed by the side-chain length of the penultimate amino acid. Proc Natl Acad Sci U S A 86:8247-8251. http://dx.doi.org/10.1073/pnas.86.21.8247.
39. Yasueda H, Kikuchi Y, Kojima H, Nagase K. 1991. In-vivo processing of the initiator methionine from recombinant methionyl human interleukin-6 synthesized in Escherichia coli overproducing aminopeptidase-P. Appl Microbiol Biotechnol 36:211-215.
40. Doerfel LK, Wohlgemuth I, Kothe C, Peske F, Urlaub H, Rodnina MV. 2013. EF-P is essential for rapid synthesis of proteins containing consecutive proline residues. Science 339:85-88. http://dx.doi.org/10.1126/science.1229017.
41. Zou SB, Hersch SJ, Roy H, Wiggers JB, Leung AS, Buranyi S, Xie JL, Dare K, Ibba M, Navarre WW. 2012. Loss of elongation factor P disrupts bacterial outer membrane integrity. J Bacteriol 194:413-425. http://dx.doi.org/10.1128/JB.05864-11.
42. Hersch SJ, Wang M, Zou SB, Moon KM, Foster LJ, Ibba M, Navarre WW. 2013. Divergent protein motifs direct elongation factor P-mediated translational regulation in Salmonella enterica and Escherichia coli. mBio 4:e00180-13. http://dx.doi.org/10.1128/mBio.00180-13.
43. Guédon E, Renault P, Ehrlich SD, Delorme C. 2001. Transcriptional pattern of genes coding for the proteolytic system of Lactococcus lactis and evidence for coordinated regulation of key enzymes by peptide supply. J Bacteriol 183:3614-3622. http://dx.doi.org/10.1128/JB.183.12.3614-3622.2001.
44. Doerfel LK, Rodnina MV. 2013. Elongation factor P: function and effects on bacterial fitness. Biopolymers 99:837-845. http://dx.doi.org/10.1002/bip.22341.
45. Tanner JJ. 2008. Structural biology of proline catabolism. Amino Acids 35:719-730. http://dx.doi.org/10.1007/s00726-008-0062-5.
46. Griffin JE, Gawronski JD, Dejesus MA, Ioerger TR, Akerley BJ, Sassetti CM. 2011. High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. PLoS Pathog 7:e1002251. http://dx.doi.org/10.1371/journal.ppat.1002251.
47. Berney M, Weimar MR, Heikal A, Cook GM. 2012. Regulation of proline metabolism in mycobacteria and its role in carbon metabolism under hypoxia. Mol Microbiol 84:664-681. http://dx.doi.org/10.1111/j.1365-2958.2012.08053.x.